No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US Stock MarketDetailed Quotes
VCNX Vaccinex
- 7.4982
- +0.3982+5.61%
Trading Jul 22 15:01 ET
11.88MMarket Cap-291P/E (TTM)
7.4999High6.6080Low65.45KVolume7.1800Open7.1000Pre Close467.30KTurnover10.67%Turnover RatioLossP/E (Static)1.58MShares64.890052wk High8.37P/B4.60MFloat Cap4.432052wk Low--Dividend TTM613.38KShs Float2568.3000Historical High--Div YieldTTM12.56%Amplitude4.4320Historical Low7.1390Avg Price1Lot Size
Intraday
- 5D
- Daily
- Weekly
- Monthly
- 1Q
- 1Y
Trade Overview
Unit: --
Capital Trend
IntradayDayWeekMonth
No Data
News
Wall Street Set to Open Flat Friday as Investors Eye Earnings Reports, FOMC Member Speeches
US stocks look set to open flat in Friday's trading session as investors take in a raft of earnings reports coming out, including those from American Express (AXP), Travelers Companies (TRV),
Investors Await Key Earnings Reports as US Futures Tread Water in Friday's Premarket
US stock futures were relatively unchanged in Friday's premarket session as investors eye a slew of earnings coming out, including those from American Express (AXP), Travelers Companies (TRV),
Express News | Vaccinex to Report Topline Data for Signal-Ad Phase 1B/2 Trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
Vaccinex Files to Sell 490,509 Shares of Common Stock for Holders
Express News | Vaccinex Completes Last Patient Visit In Randomized, SIGNAL-AD Phase 1b/2 Study Of Pepinemab Treatment For Alzheimer's Disease
Express News | Vaccinex Reports Completion of Last Patient Visit in Randomized, Signal-Ad Phase 1B/2 Study of Pepinemab Treatment for Alzheimer’s Disease
Comments
Follow Our Official Telegram Channel tynkrlab
$Dow Jones Industrial Average(.DJI.US$ rose by 0.59% to a new record high, closing at 41,211.12. In contrast, the $S&P 500 Index(.SPX.US$ fell by 1.39%, and the $Nasdaq Composite Index(.IXIC.US$ dropped by 2.76%. Tech stocks faced significant pressure, contributing to the mixed market performance.
Key Drivers
1. Strong Performers: $UnitedHealth(UNH.US$, $Johnson & Johnson(JNJ.US$, and $Cisco(CSCO.US$ l...
$Dow Jones Industrial Average(.DJI.US$ rose by 0.59% to a new record high, closing at 41,211.12. In contrast, the $S&P 500 Index(.SPX.US$ fell by 1.39%, and the $Nasdaq Composite Index(.IXIC.US$ dropped by 2.76%. Tech stocks faced significant pressure, contributing to the mixed market performance.
Key Drivers
1. Strong Performers: $UnitedHealth(UNH.US$, $Johnson & Johnson(JNJ.US$, and $Cisco(CSCO.US$ l...
5
$Vaccinex(VCNX.US$
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
Vaccinex (Nasdaq: VCNX) will present topline data for its phase 1b/2 SIGNAL-AD study of pepinemab in Alzheimer's disease at the Alzheimer's Association International Conference on July 31, 2024. The study aims to evaluate the safety and efficacy of targeting reactive astrocytes with pepinema...
Vaccinex to report topline data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease at the Alzheimer’s Association International Conference, Philadelphia, July 31, 2024
Vaccinex (Nasdaq: VCNX) will present topline data for its phase 1b/2 SIGNAL-AD study of pepinemab in Alzheimer's disease at the Alzheimer's Association International Conference on July 31, 2024. The study aims to evaluate the safety and efficacy of targeting reactive astrocytes with pepinema...
$Vaccinex(VCNX.US$
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
Vaccinex announced the completion of the last patient visit in its Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's Disease (AD). The database lock is expected in June, with key outcomes to be reported in July.
Pepinemab targets astrocyte reactivity and neuroinflammation, believed to accelerate AD progression. Key endpoints incl...
Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease
Vaccinex announced the completion of the last patient visit in its Phase 1b/2 SIGNAL-AD study of pepinemab for Alzheimer's Disease (AD). The database lock is expected in June, with key outcomes to be reported in July.
Pepinemab targets astrocyte reactivity and neuroinflammation, believed to accelerate AD progression. Key endpoints incl...
Read more
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
%Chg